Today’s challenge concerning tissue damage or cell death, is to prolong the lifespan of cells thus giving physicians more time to perform the appropriate intervention and stop the ongoing pathological process. Whether patients suffer a myocardial infarction, undergo elective surgical proceedures, receive cell or organ transplants, there is always a risk of cell damage due to ischemia and hypoxia leading to cell death. The Eribis peptides will lower metabolic needs in the tissue and by that improve the overall patient outcome.

Eribis peptides have been characterised in preclinical study models where receptor binding, analgesia, as well as MI have been performed delivering promising results. The Proof of Concept studies are done and have confirmed the cardio protective effects. The candidate drug (CD) is selected and the preclinical and safety package will be started in 2010. The clinical development will be initiated during 2011 with acute MI as the selected clinical indication. The drug will be administered through intravenous injection.

Eribis’s Candidate Drug will decreases the ischemic damage of heart muscle up to 25 % ARR, providing a more effective protection than standard treatment, according to the pre-clinical studies done to date. It has in animal studies been shown that the peptides have organ and tissue protective properties, including anti-hypoxic activity which will be investigated further for other product indications.